OCT 09, 2018 03:19 PM PDT

Weight Loss Drug Reduces Incidence of Diabetes

WRITTEN BY: Nouran Amin

Image via The San Diego Tribune

A clinical trial weight loss drug, by the name of Lorcaserin—manufactured by Eisai Inc., was found to reduce the risk of diabetes by 19 percent in patients with pre-diabetes as well as reducing the risk of diabetic microvascular complications such as microalbuminuria. "We recently presented findings showing that use of lorcaserin resulted in modest but sustained weight loss among obese and overweight patients without increasing risk of heart attack and stroke," said co-lead author Erin Bohula, MD, DPhil, a BWH cardiovascular medicine specialist. "Now we report that, when added to lifestyle interventions, lorcaserin significantly reduced incidence of diabetes, increased rates of diabetes remission, and reduced the risk of diabetic microvascular complications."

The findings of the study were recently published in The Lancet.

"Taken together, these findings reinforce the notion that modest, durable weight loss can improve cardiometabolic health and supports the role of lorcaserin as an adjunctive therapy in chronic weight management," explains co-lead author Benjamin Scirica, MD, also a fellow cardiovascular medicine specialist at BWH and senior investigator for the TIMI Study Group. "It provides another tool in the armamentarium, beyond diet and exercise, for patients hoping to achieve and maintain weight loss. And, happily, as we saw, even relatively modest weight loss can improve the diabetes control in those with diabetes and reduce the development of diabetes in those at risk."

In addition to reducing the risk of diabetes and diabetic microvascular complications (e.g. persistent microalbuminuria, diabetic retinopathy or diabetic neuropathy), as well as decreasing weight, Lorcaserin was found to increase the remission rate to the rate of hyperglycemia in patients with diabetes. Additionally, despite patients having well-controlled diabetes at the start of the clinical studies, lorcaserin resulted in a reduction of hemoglobin A1c levels (a measure of glucose control).

However, there were side effects of lorcaserin with 6.6 percent of the patients reporting dangerously low levels of blood sugar known as Hypoglycemia. Cases of severe hypoglycemia requiring hospitalization were especially prevalent among patients taking medications known to have hypoglycemic effects such as insulin or sulfonylurea’s, medications known to result in hypoglycemia.

 

 

Such findings has encouraged researchers to highlight the importance of carefully titrating agents associated with the risk hypoglycemic events, especially if patients are on weight loss.

"Given the global prevalence of obesity and its association with type 2 diabetes and complications that can cause death or greatly diminish quality of life, we need therapeutic strategies that can be added to lifestyle modification to prevent and control diabetes," said Scirica. "This rigorous and large-scale randomized study demonstrates the potential for improving glycemic control when adding a weight loss agent to a treatment plan."

Source: Brigham and Women’s Hospital

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
OCT 31, 2018
Cancer
OCT 31, 2018
Researchers identify a protein marker that induces dormancy in metastatic breast cancer
Researchers at the Mount Sinai hospital identified for the first time a protein marker that could indicate whether breast cancer will further metastasize or remains in a dormant state accordi...
NOV 29, 2018
Cannabis Sciences
NOV 29, 2018
Want to Smoke Weed? For Science?
Clinical trials are a necessary part of the drug approval process. All drugs on the market, even the over-the-counter drugs, have gone through clinical tri...
DEC 09, 2018
Drug Discovery
DEC 09, 2018
Insect Venom Can Someday Combat Antibiotic-Resistant Infections
Insect venom, such as those secreted by wasps and bees, are considered an insect’s immune system defense because of its richness in bacterial killing...
DEC 16, 2018
Health & Medicine
DEC 16, 2018
Important Biomedical Research At Risk Of Being Defunded
In September the Department of Health and Human Services (D.H.H.S.) released a statement citing “serious regulatory, moral and ethical considerations...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer
Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combinatio...
Loading Comments...